Aventura • South Florida
Ketamine in the News
Selected recent coverage and research about ketamine therapy.
¡Hablamos Español!
Aventura • South Florida
Selected recent coverage and research about ketamine therapy.
¡Hablamos Español!
Recent articles and stories highlighting the potential benefits of ketamine therapy.
HFB Podcast · 2026
Dr. Jacob Silverstone discusses ketamine therapy, trauma healing, and the approach at Rewired Ketamine in Aventura.
International Business Journal · October 15, 2026
International Business Journal profiled Rewired Ketamine’s Aventura clinic, noting more than 3,000 guided infusions and the clinic’s reported outcomes for patients who had not found relief with standard treatments. Locally owned, Spanish-speaking, in-clinic care.
Woman’s Week · October 15, 2026
Woman’s Week covered Rewired Ketamine’s Aventura practice, highlighting 3,000+ infusions and REMS certification for Spravato. The piece notes in-clinic IV ketamine and esketamine options with integration support.
Neuropsychiatric Disease and Treatment · September 2025
Raza and colleagues reviewed intranasal esketamine (Spravato) for major depression and treatment-resistant depression. Trials such as TRANSFORM-2, SUSTAIN-1, and ASPIRE are cited for rapid antidepressant effects, often within hours, through NMDA receptor antagonism. Spravato is given in clinic under REMS. Reported effects include dissociation and blood pressure changes. A 2025 review reported lower rates of sexual side effects than many SSRIs; individual results vary. This is a research summary, not a treatment claim.
Revista Veritas · September 30, 2026
A narrative review of how opioid exposure can increase pain sensitivity, and why ketamine and magnesium are the agents most directly tied to the NMDA receptor in perioperative research. It supports an opioid-sparing role in acute surgical pain. It is not a depression-treatment claim.
SciTechDaily · September 21, 2026
SciTechDaily covers Texas A&M research in Translational Psychiatry. Veterans over 55 received a single ketamine infusion. EEG patterns kept changing over the following week. Greater information-sharing in brain signals at 24 hours was linked to more symptom relief by day seven. Early work on possible response markers — not a clinic treatment claim.
Reuters · September 15, 2026
Reuters reviews the clinical and regulatory landscape after an FDA public meeting on psychedelic therapies. Most remain Schedule I in the U.S. Trials are furthest along for severe depression and PTSD. The piece also notes Spravato (esketamine) is FDA-approved for treatment-resistant depression, and that ketamine is authorized as an anesthetic and sometimes used off-label for depression. Research is moving quickly; results and access still vary.
Nature Structural & Molecular Biology · 2026
A recent paper in Nature Structural & Molecular Biology advances our understanding of NMDA receptor biology — the same receptor system central to how ketamine works in the brain.
CNN · September 2025
A personal account of how ketamine therapy helped with long-standing anxiety and depression.
Us Weekly · 2026
Celebrities including Chrissy Teigen, Elon Musk, Molly O’Connell and others share their experiences with ketamine therapy.
DAV · 2025
A Green Beret discusses how ketamine helped him recover from PTSD and reclaim daily life.
Stanford Medicine · May 2026
New research from Stanford shows a promising way to extend ketamine’s anti-suicidal benefits.
Billboard · July 2026
Musicians and artists openly discuss the potential of ketamine and other psychedelic-assisted therapies.
Rutgers University · 2024
New research from Rutgers suggests ketamine may help reduce symptoms of chronic fatigue.
News-Medical.net · July 2026
New research shows ketamine may increase neuroplasticity in female brains by activating microglia, highlighting important sex differences that could help refine future depression treatments.
Medscape News Canada · August 2026
A small Toronto pilot study and the “Montreal model” explore pairing ketamine with weekly psychotherapy. Early findings suggest the combination may support neuropathic pain and help extend ketamine’s short-lived mental-health benefits.
Futurity · Texas A&M University · September 2026
Texas A&M researchers found time-specific brain-activity patterns after ketamine in older adults with treatment-resistant depression. Different information-organization patterns appeared at 1 hour, 24 hours, and 7 days. Greater brain-wide information sharing at 24 hours was linked to better symptom improvement at day 7. The work is aimed at possible biomarkers of response in late-life depression — not a guarantee of outcome.
Book a free consultation. No pressure — just honest answers and a clear path forward.
Book Free Consultation